Ewing Sarcoma

Subsequently, targeting GPL biosynthesis (FSG67) restored DNA-damaging agent (SN-38) sensitivity in SLFN11-deficient EWS model, revealing a potential metabolic vulnerability to overcome chemoresistance. Furthermore, SLFN11 knockout tumors exhibited an elevated phosphocholine/glycerophosphocholine ratio, offering a potential non-invasive diagnostic biomarker.

P=N/A, N=90, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital

P=N/A, N=36, Not yet recruiting, Peking University Shougang Hospital; Peking University Shougang Hospital

P1, N=24, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.

Key messages Round cell sarcomas share many morphological similarities, so the differential diagnosis can be broad; however, subtle differences between tumours can aid the final diagnosis. Nevertheless, most round cell sarcomas require molecular studies for accurate classification, and cytological specimens are usually high quality material for such ancillary techniques.

In a Ewing sarcoma xenograft model, wave bioreactor-cultured CAR-T cells showed a greater percentage of memory-like tumor-infiltrating lymphocytes. Collectively, these results indicate that wave bioreactor-based dynamic cultivation promotes mitochondrial metabolic reprogramming, which is characterized by an enhanced TCA cycle and sustained oxidative phosphorylation, thereby sustaining CAR-T cell functionality and providing a robust platform for the manufacturing of potent and durable cellular therapeutics.

These findings identify circZNF609 as a novel post-transcriptional regulator of EWS::FLI1 and establish its critical role in EwS pathogenesis. Our results suggest that targeting the circZNF609/miR-145-5p/EWS::FLI1 axis may offer a promising therapeutic strategy for EwS.

P1, N=18, Recruiting, Children's National Research Institute | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Jan 2026

Olaparib combined with irinotecan demonstrated activity in pediatric tumors which was enriched among tumors that exhibited aneuploidy.

The patient underwent subtotal maxillectomy with intraoperative margin assessment, achieving complete surgical excision with histologically negative margins, followed by adjuvant chemotherapy with epirubicin, cisplatin, and ifosfamide, as well as localized radiotherapy. At 18 months of clinical and radiologic follow-up, there was no evidence of local recurrence, with preserved oral function and satisfactory aesthetic outcomes on clinical evaluation. This report highlights the importance of considering malignant small round cell tumors in rapidly enlarging maxillofacial lesions and emphasizes the role of multidisciplinary management in achieving sustained local disease control while preserving postoperative function.

P2, N=59, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Feb 2025

Liquid biopsy holds strong potential for transforming bone tumor care. Its clinical adoption depends on further validation through standardized methods and large-scale studies.